The largely dormant biotech IPO market started sizzling Friday, with two Phase III drug developers sending in their pitches for Nasdaq debuts this fall.
After Friday’s closing bell, the neuroscience biotech Neumora submitted its paperwork to go public, a day after RayzeBio disclosed its…
Click here to view original post
